Clinical trials: Ticagrelor
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Acute Coronary Syndrome, Coronary Stent Implantation
A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients
This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS…
- Trial name
- TIGER (NCT04255602)
- Testing
- Ticagrelor 60mg, Ticagrelor 90mg
- Where
- 8 sites in China
- Volunteers
- 2,120 people
- Sponsor
- Shanghai Tong Ren Hospital
Rheumatoid Arthritis
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
This is an open label study to assess the improvement in the Disease Activity Score for 28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who have active disease despite MTX therapy (as…
- Trial name
- TIMERA (NCT02874092)
- Testing
- Ticagrelor, MTX therapy
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Ticagrelor
De-escalation of Ticagrelor in Post PPCI
Primary objective: to evaluate the efficacy and safety of De-escalation to lower dose Ticagrelor (60 mg BID) plus Aspirin (75 mg OD) versus continuation of standard dose Ticagrelor (90 mg BID) plus Aspirin (75 mg OD), 1 month…
- Trial name
- NCT05831462
- Testing
- Ticagrelor 60mg
- Volunteers
- 400 people
- Sponsor
- Assiut University
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome, Acute Myocardial Infarction
Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome
The investigators hypothesized that ticagrelor may enhance endothelial healing after DES implantation by increasing adenosine concentrations by the inhibition of adenosine uptake into erythrocytes, compared to clopidogrel.
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina (Intermediate Coronary Syndrome)
- Trial name
- NCT02037412
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Yonsei University
Hemorrhage, Urgent Surgery
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who…
- Conditions
- Hemorrhage, Urgent Surgery, Invasive Procedure
- Trial name
- REVERSE-IT (NCT04286438)
- Testing
- Bentracimab (PB2452) Infusion
- Where
- 68 sites in United States, Austria and 11 more
- Volunteers
- 226 people
- Sponsor
- SFJ Pharmaceuticals, Inc.
End Stage Renal Disease, Vascular Access Patency
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited.
- Trial name
- NCT02335099
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Virginia
Coronary Artery Disease
A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI
PIONEER IV CHINA is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system at 12 months follow-up.
- Trial name
- NCT05015699
- Testing
- HT Supreme
- Sponsor
- Sino Medical Sciences Technology Inc.
Diabetes Mellitus, Coronary Disease
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
In recent years numerous studies have shown that the response of patients to the anti-platelet drug clopidogrel is widely variable.
- Trial name
- MATTIS-D (NCT01643031)
- Testing
- Ticagrelor, Continued clopidogrel
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Rabin Medical Center
Acute Coronary Syndrome
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes
The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes
- Trial name
- OPTIMA (NCT02319941)
- Testing
- ticagrelor, clopidogrel
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Seung-Jung Park
Non ST Segment Elevation Acute Coronary Syndrome
Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02415803
- Testing
- low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Artery Disease, Endothelial Function
Offset of Ticagrelor's Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry (EndoPAT Assay)
Ticagrelor administration, whose molecule resembles to adenosine, led to reduction in overall mortality and thrombotic cardiovascular (CV) events when directly compared to clopidogrel in the PLATO trial, implicating possible…
- Trial name
- NCT01957527
- Testing
- Peripheral arterial tonometry (EndoPAT)
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- University of Patras
Acute Coronary Syndrome
Effect of Free Ticagrelor Fraction on Platelet Membrane Post MI
The purpose of this study is to assess: the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor ticagrelor and its metabolite levels by LC-MS/MS
- Trial name
- PLATIME (NCT03658005)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Infarction, Myocardial Infarction
Which Platelet Function Test Best Reflects the In Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite?
Ticagrelor is a direct-acting, reversible platelet P2Y12 receptor inhibitor recommended by the recent European Society of Cardiology guidelines in patients with acute coronary syndromes (ACS) (class of recommendation I, level of…
- Conditions
- Infarction, Myocardial Infarction, Cardiovascular Diseases, Heart Diseases
- Trial name
- HARMONIC (NCT02690454)
- Where
- Poland
- Volunteers
- 45 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention…
- Trial name
- ATLANTIC (NCT01347580)
- Testing
- Ticagrelor
- Where
- 96 sites in Algeria, Australia and 11 more
- Volunteers
- 1,875 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome (ACS)
Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes
Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS
- Trial name
- Real-TICA (NCT02265068)
- Testing
- Ticagrelor
- Where
- 6 sites in Germany
- Volunteers
- 700 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Ticagrelor, Aspirin
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.
- Conditions
- Ticagrelor, Aspirin, Platelet Dysfunction Due to Drugs, Transfusion
- Trial name
- REVSTARTS (NCT03005704)
- Testing
- Antiplatelet treatment
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Ischemic Stroke
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through…
- Trial name
- NCT06202755
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University
Coronary Artery Disease, Depression
Antiplatelet Therapies in Patients With Depression and Coronary Disease
Depression after an acute coronary syndrome (ACS) but also at any time after CAD diagnosis, is highly associated with death, and it predicts mortality more than any other risk factor, comorbidity or follow-up events, suggesting…
- Trial name
- ENHANCE (NCT05821062)
- Testing
- standard Aspirin (ASA) + clopidogrel (CLP) therapy, standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy, standard ASA therapy
- Where
- 2 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Centro Cardiologico Monzino